Covid-19 Innovation Challenges by Innoget posted this:COVID-19 Rapid Diagnostic KitDesigning and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19.
TEC Edmonton posted this:Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion InhibitorsA series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.
Universitat Politècnica de Catalunya - UPC posted this:Simple, comfortable hand-held patient interface for fast ECG measurementsA simple, comfortable patient interface that reduces the time to obtain the ECG (lead I) and minimises external differential-mode interference on it has been patented and developed. The device uses dual dry electrodes placed on a mechanical support that the patient touches, holds or grasps, and can be easily applied wherever a fast ECG measurement can be of interest. A laboratory prototype is available that can be wireless connected to any convenient user interface such as a PC. Partners to further develop the device and/or to establish commercial agreements along with technical cooperation are sought.
Centre Technology Transfer CITTRU posted this:Hospital emissions: N2O abatementThe subject of the offer is catalyst, α-Al2O3 supported, dedicated to reduce the emission of N2O in a low temperature range. Application: Hospital gases collectors, nitric acid production plant emitters, adipic acic production plant emitters.
Alexander Kvashnin posted this:
Director at Center for Technology Transfer and Commercialization of Novosibirsk State University
Alphanosos posted this:Effiskin(r), a veterinary hygiene product adapted to dogs with pyoderma prone skinsWe are looking for distributors and/or licensees for Effiskin(r). This hygiene product is a lotion formulated around our patent pending alternative to antibiotics and chlorhexidine, a WECMEP (Water Extracts of Complex Mixes of Edible Plants) with a great safety profile. Successful animal model results and user testimony are available. Available as bulk formulation or finished product (spray), also for rebranding.
Small and Medium Enterprise
Creative Biogene posted this:Human HTR2B-FLAG Stable Cell Line-HEK293T5-HT2B (5-hydroxytryptamine receptor 2B) is a receptor for serotonin. It is expressed in many peripheral and central nervous system tissues, including stomach fundus, liver kidney, muscle, intestine and brain. 5-HT2B receptors are responsible for many cardiovascular and central nervous system functions, such as blood vessel contraction, platelet shape changes, neuronal sensitization to tactile stimuli, and mediation of the hallucinogenic effects of phenylisopropylamin hallucinogens.
Technology Transfer Office
RAMOT at Tel Aviv University Ltd. posted this:Iron oxide nanoparticles (IOP) for the treatment of acute myocardial infarction (AMI) and other inflammatory conditionsA novel approach for the treatment of AMI has been developed using IOPs. IOPs, when injected into the infarcted myocardium, lead to improved heart function after MI. IOPs activate anti-inflammatory macrophages and thus promote tissue healing and repair and prevent myocardial remodeling and dysfunction. Potential Applications IOPs can be used to treat AMI and other inflammatory conditions associated with pro-inflammatory activated macrophages and to promote tissue healing and repair. Advantages ? IOPs are nontoxic ? IOPs are FDA approved for use in humans for MRI imaging Stage In vivo studies in mouse and rat models of MI and heart failure Project ID : 10-2011-247
shimmer Research posted this:Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patientsManaging the huge influx of patients in hospitals is one of the most critical challenges of the current COVID-19 pandemic. Shimmer’s Bioimpedance Monitor has the potential to help manage this challenge by monitoring HR, respiration rate and depth and the increase in fluid in the lungs to triage and remotely monitor patients. Background Bioimpedance, specifically across the lungs, has long been studied in Chronic Heart Failure (CHF) and Acute Respiratory Distress Syndrome (ARDS). This measurement provides useful indicators of respiration, including rate, volume, and fluid in the lungs. Because COVID-19 attacks the lungs, these measurements provide clear indications of the progression of the disease. This information can be used in many ways, potentially including: • Monitoring patients remotely at home to determine, if and when, they will need to be admitted to the hospital • Monitoring patients in a hospital to determine when they need more aggressive treatment (e.g., ventilators) • Enabling the earlier release of non-acute patients because of the ability to monitor at home • Adjusting the treatment depending on the rate of progression of disease
UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera
Universidad de Alcalá-OTRI posted this:Universal sensor platform for immunoassayThe research group in Bioelectrochemistry and Biosensors of the University of Alcalá has developed a method for the construction of a universal analytical device that allows the adaptation of any ELISA format to an immunosensor format, in order to develop simple, low cost and easy to use sensors. This device is based on the sequential deposition of self-assembled monolayers of polymers and affinity elements, applicable for the detection and quantification of any analyte or target antigen in a liquid sample, which allows the development of "on-demand" immunosensors. The group looks for companies or institutions from agro-food, bio-sanitary and environmental sector, interested in reaching collaboration agreements, commercial agreements with technical assistance or patent licensing.